| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. | Director | Common Stock | 161,729 | $423,729 | $2.62 | 10 Jun 2025 | Direct |
| Aravive, Inc. | Director | Stock Option (Right to Buy) | 97,063 | 23 Sep 2022 | Direct | ||
| Akebia Therapeutics, Inc. | Director | Stock Option (Right to buy) | 53,600 | 10 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | 10 Jun 2025 | 2 | $0 | 4 | Director | 11 Jun 2025, 17:14 |
| AKBA | Akebia Therapeutics, Inc. | 06 Jun 2024 | 2 | $0 | 4 | Director | 10 Jun 2024, 16:19 |
| AKBA | Akebia Therapeutics, Inc. | 06 Jun 2023 | 2 | $0 | 4 | Director | 08 Jun 2023, 16:08 |
| /report/000143774922023060-rogers-michael-w-2022-09-23 | Aravive, Inc. | 23 Sep 2022 | 1 | $0 | 4 | Director | 26 Sep 2022, 16:07 |
| AKBA | Akebia Therapeutics, Inc. | 08 Jun 2022 | 2 | $0 | 4 | Director | 09 Jun 2022, 16:58 |
| /report/000143774921022011-rogers-michael-w-2021-09-10 | Aravive, Inc. | 10 Sep 2021 | 1 | $0 | 4 | Director | 13 Sep 2021, 16:06 |
| AKBA | Akebia Therapeutics, Inc. | 02 Jun 2021 | 2 | $0 | 4 | Director | 03 Jun 2021, 17:27 |